GlassScriptPhysician profile
Kenneth C Sabatino
NPI 1003805664
$3,447.25
in general payments reported to CMS, 2019-2025
29 companies · $373 in 2025
The $373 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,366 · 2020: $196 · 2021: $188 · 2022: $140 · 2023: $384 · 2024: $801 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,459 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,459.11 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $956.42 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $752.68 | 2019-2025 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $399.81 | 2019-2024 | Farxiga |
| Sanofi-Aventis U.S. LLC | $187.98 | 2019-2020 | |
| W. L. Gore & Associates, INC. | $146.45 | 2023 | Gore Excluder Aaa Endoprosthesis |
| Astellas Pharma US INC | $142.17 | 2019-2023 | |
| Pfizer INC. | $124.52 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $119.87 | 2019-2020 | |
| Amarin Pharma, INC. | $84.80 | 2019-2020 | |
| Boston Scientific Corporation | $80.25 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $79.15 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $56.87 | 2019-2021 | |
| Cook Medical LLC | $46.08 | 2024 | Zilver Ptx |
| Regeneron Healthcare Solutions, INC. | $37.26 | 2019 | |
| Arbor Pharmaceuticals, INC. | $33.31 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $32.19 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $31.57 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.47 | 2019 | |
| Cleerly, INC. | $28.18 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Csl Behring | $27.13 | 2019 | |
| Abbott Laboratories | $24.81 | 2019 | |
| Bardy Diagnostics, INC. | $13.50 | 2019 | |
| Nuwellis, INC. | $11.78 | 2019 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Sabatino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.